A5059564746- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- Health disparities and outcomes
- CRISPR and Genetic Engineering
- Chronic Disease Management Strategies
- Geriatric Care and Nursing Homes
- Mosquito-borne diseases and control
- Pneumocystis jirovecii pneumonia detection and treatment
- HIV-related health complications and treatments
- Health and Wellbeing Research
- RNA Interference and Gene Delivery
University of Washington
2024
University of Nebraska Medical Center
2019-2023
Treatment of HIV-1 ADA -infected CD34+ NSG-humanized mice with long-acting ester prodrugs cabotegravir, lamivudine, and abacavir in combination native rilpivirine was followed by dual CRISPR-Cas9 C-C chemokine receptor type five (CCR5) proviral DNA gene editing. This led to sequential viral suppression, restoration absolute human CD4 + T cell numbers, then elimination replication-competent virus 58% infected mice. Dual CRISPR therapies enabled the excision integrated cells contained within...
Human immunodeficiency virus type one (HIV-1) tissue compartments are established soon after viral infection. However, the timing in which gains a permanent foothold and cellular factors that control early viral-immune events incompletely understood. These critical studies of HIV-1 pathogenesis development reservoirs antiretroviral therapy. Moreover, affecting permanence viral-tissue interactions underlie barriers designed to eliminate To this end we investigated temporal spatial host during...
Detection of latent human immunodeficiency virus type 1 (HIV-1) in "putative" infectious reservoirs is required for determining treatment efficiency and viral elimination strategies. Such tests require induction replication competent provirus quantitative testing load validation. Recently, infected humanized mice were employed the development such by employing a murine outgrowth assay (mVOA). Here HIV-1 proviral DNA was amplified from virus-infected lymphoid cell reconstituted mice. Cells...
Evidence-based programs (EBPs) for health promotion were developed to reach older adults where they live, work, pray, and play. When the COVID-19 pandemic placed a disproportionate burden on living with chronic conditions community-based organizations that support them, these in-person shifted remote delivery. While EBPs have demonstrated effectiveness when delivered in person, less is known about outcomes remotely.
<sec> <title>BACKGROUND</title> Evidence-based programs (EBPs) for health promotion were developed to reach older adults where they live, work, pray, and play. When the COVID-19 pandemic placed a disproportionate burden on living with chronic conditions community-based organizations that support them, these in-person shifted remote delivery. While EBPs have demonstrated effectiveness when delivered in person, less is known about outcomes remotely. </sec> <title>OBJECTIVE</title> This study...